BlossomHill Therapeutics IPO
BlossomHill Therapeutics, Inc. · Clinical-stage oncology biopharmaceuticals
- Issue price
- $16per share
- Issue size
- $150M93,75,000 shares
- Face value
- To be announcedper equity share
- Lot size
- To be announcedMin. investment shown once set
- PricingThu, 2026
Information only, not investment advice. This page provides information compiled from official SEC filings for information purposes only. It is not investment advice or a recommendation to buy or sell any security. IPO investments involve risk, including loss of principal; read the prospectus carefully before investing.
Issue details
- Issue type
- Firm commitment, fresh issue
- Fresh issue
- 93,75,000 shares ($139.5M)
- Offer for sale
- None
- Total issue
- 93,75,000 shares ($150M)
- Face value
- —
- Listing at
- Nasdaq
Source: Final prospectus (Form 424B4) dated 7 Aug 2026Updated
Special quotas
- directed_share_program
- 93,750 shares
Source: Final prospectus (Form 424B4) dated 7 Aug 2026Updated
Valuation
Year ended December 31, 2024- EPS (basic)
- -$13.4
- EPS (diluted)
- -$13.4
- EPS (basic) (Year ended December 31, 2025)
- -$24.83
- EPS (diluted) (Year ended December 31, 2025)
- -$24.83
- EPS (basic) (Three months ended March 31, 2025)
- -$4.39
- EPS (diluted) (Three months ended March 31, 2025)
- -$4.39
- EPS (basic) (Three months ended March 31, 2026)
- -$8.14
- EPS (diluted) (Three months ended March 31, 2026)
- -$8.14
Source: Final prospectus (Form 424B4) dated 7 Aug 2026Updated
Financials
Standalone, restated · ₹ crore| Period ended | 31 Mar 20263 months | 31 Dec 202512 months | 31 Mar 20253 months | 31 Dec 202412 months |
|---|---|---|---|---|
| Profit after tax | -2.10 | -6.06 | -1.05 | -3.07 |
| Net worth | -15.21 | — | — | — |
| Total assets | 14.34 | — | — | — |
12 months vs 12 months: profit after tax −97.3%. Periods shorter than 12 months are shown as reported and are not annualised.
Source: Final prospectus (Form 424B4) dated 7 Aug 2026Updated
About the company
BlossomHill is a clinical-stage biopharmaceutical company developing small molecule cancer medicines using a chemistry-based, structure-driven drug design approach. Its lead candidate, BH-30643, targets EGFR-mutant lung cancer, and it also has a CLK inhibitor in Phase 1 trials for leukemia and a preclinical pan-KRAS candidate.
- Incorporated
- —
- Industry
- Clinical-stage oncology biopharmaceuticals
- Sector
- Healthcare and Pharma
- Website
- bhtherapeutics.com
Source: Final prospectus (Form 424B4) dated 7 Aug 2026Updated
Promoters and shareholders
| Name | Before issue | After issue |
|---|---|---|
| J. Jean Cui, Ph.D. and Y. Peter Li, Ph.D., MBA and related affiliates | 18.70% | 13.00% |
| Entities affiliated with Cormorant Asset Management LP | 15.50% | 10.80% |
| OrbiMed Private Investments VIII, LP | 9.80% | 6.80% |
| Vivo Innovation Fund II Holdings, L.P. | 7.00% | 4.90% |
| Janus Henderson Biotech Innovation Master Fund Limited | 5.30% | 3.70% |
Source: Final prospectus (Form 424B4) dated 7 Aug 2026Updated
Objects of the issue
₹ crore| Purpose | Amount |
|---|---|
| Advance clinical development of BH-30643 in EGFR-mutant NSCLC, including the ongoing Phase 1/2 trial and a planned registrational Phase 2 trial | 7.00 |
| Advance clinical development of BH-30236 in AML, HR-MDS and other hematological malignancies | 2.00 |
| Complete IND-enabling studies, submit an IND and start a Phase 1 trial of BH-501284 | 1.50 |
| Other research and development, capital expenditures, working capital and general corporate purposes | Set with price |
Source: Final prospectus (Form 424B4) dated 7 Aug 2026Updated
Strengths and risks
Our summary of what the offer document statesSource: Final prospectus (Form 424B4) dated 7 Aug 2026Updated
Contacts
Source: Final prospectus (Form 424B4) dated 7 Aug 2026Updated
After listing
Listing price, day-one high and low, and the change from the issue price ($16) appear here after the shares list on Nasdaq.
Work out the gain or loss on allotted shares after charges →
Frequently asked questions
What is the BlossomHill Therapeutics IPO price band?
The final issue price is $16 per share.
Where will BlossomHill Therapeutics shares list?
On Nasdaq.
How will the money raised be used?
$70M for , $20M for , $15M for , and the rest for the other stated purposes.
Related IPOs
More healthcare and pharma IPOs
All Healthcare and Pharma IPOs →Also managed by J.P. Morgan Securities LLC
- WaterBridge Infrastructure LLC$20Listed
- Netskope$19Listed
- Pattern Group$14Listed
- Black Rock Coffee Bar$20Listed
Spotted something wrong?
Our data comes from official offer documents, but mistakes can slip through. Report an error and tell us which figure looks wrong and where you saw the correct one (the offer-document page number helps). For anything else, see Contact.